Abstract
Seasonal influenza causes substantial morbidity and mortality in the United States. The U.S. Centers for Disease Control and Prevention (CDC) uses a compartmental framework to estimate the annual disease burden and burden prevented by vaccination for all influenza types and subtypes combined. However, these estimates do not capture underlying shifts in disease burden caused by different circulating influenza virus types or subtypes. We demonstrate an extension of the current framework to estimate disease burden and burden prevented by vaccination for influenza A virus subtypes A(H1N1) and A(H3N2), and influenza type B viruses. We applied this method to data from the 2016/17 to 2019/20 seasons that include age- and virus-specific hospitalizations and vaccine effectiveness estimates, and age-specific vaccination coverage estimates. We estimated the number of symptomatic illnesses, medically-attended illnesses, hospitalizations, and deaths caused by each virus, and the corresponding number prevented by vaccination. Disease burden and vaccine-prevented burden varied substantially by season, age, and virus type or subtype. The greatest disease burden was estimated in 2017/18, whereas 2019/20 had the greatest burden prevented by vaccination. Influenza A viruses contributed most to disease burden in all seasons. Vaccination against influenza B viruses prevented the largest percentage of hospitalizations among children and adults <65 years, whereas vaccination against A(H1N1) prevented the largest percentage of hospitalizations among adults ≥65 years. Overall, our results highlight complex variability in influenza disease burden by season, age, and virus type and subtype. These findings can be used to improve understanding of the factors impacting influenza disease burden each season and to enhance communications of the value of influenza vaccination.
Highlights
Estimates of disease burden and vaccine-prevented burden inform influenza guidance.
Contributions to burden from each virus type and subtype vary by season and age.
A(H3N2) caused the greatest total disease burden from the 2016/17 to 2019/20 seasons.
Children <18 years experienced greater influenza B burden compared with other ages.
Vaccination against A(H1N1) and B prevented the greatest percentage of severe disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data were the result of secondary analyses. The Centers for Disease Control and Prevention determined that the study met the requirement for public health surveillance, and institutional review board (IRB) approval and patient consent were not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Data Availability
All data were the result of secondary analyses and approved for use in the study. The majority are publicly available and the relevant links are cited in the text. A small portion are not publicly available due to privacy restrictions but are available upon reasonable request to the authors. The Centers for Disease Control and Prevention determined that the study met the requirement for public health surveillance, and institutional review board (IRB) approval and patient consent were not required.
Data availability statement
All data were the result of secondary analyses. The majority are publicly available and the relevant links are cited in the text. A small portion are not publicly available due to privacy restrictions but are available upon reasonable request to the authors.
